Editorials
Are Physician-derived Joint Counts Obsolete?
E.C. Keystone .......................................................... 883
Mismatch Between Skills of Patients and Tools in Use:
Might Literacy Affect Diagnoses and Research?
R.E. Rudd ........................................................... 885
The Challenges of Quantifying the Risk of Serious
Infection with Tumor Necrosis Factor Antagonist Therapy
J. Leombruno ....................................................... 887
Atherosclerosis in Rheumatoid Arthritis: What to Look For
in Studies Using Carotid Ultrasound
T. Del Rincon ....................................................... 890

Review
More Night Than Day — Circadian Rhythms in Polymyalgia
Rheumatica and Ankylosing Spondylitis
C.M. Spies, M. Cutolo, R.H. Straub, G.R. Burmester, F. Buttgerit . . 894

Articles
Genetic Variations in Genes Encoding RANK, RANKL,
and OPG in RA: A Case-Control Study
G. Assmann, J. Koenig, M. Pfreundschuh, et al. .......................... 900
Multiplex Screening of 22 SNP in 7 Toll-like Receptors:
An Association Study in RA C. Enveold, T.R.D. Radstake,
M.J.H. Coenen, et al .............................................. 905
Decreased Circulating CD28– T Cells in Patients with RA
Treated with Abatacept Are Correlated with Clinical
Response M. Scarsi, T. Ziglioli, P. Airò ................................ 911
Efficacy and Safety of Retreatment in Patients with RA
with Previous Inadequate Response to TNF Inhibitors:
Results from the SUNRISE Trial
P.J. Mease, S. Cohen, N.B. Gaylis, et al. ................................. 917
Observational Studies of Infections in RA: A Metaanalysis
of TNF Antagonists S. Bernatsky, Y. Habel, E. Rahme . . . . . 928
Reproducibility of Joint Swelling Assessments in
Long-lasting RA: Influence on Disease Activity Score-28
Values (SEA-Repro Study Part I)
Reproducibility of Joint Swelling Assessment by Sonography
in Patients with Long-lasting RA (SEA-Repro Study Part II)
S. Jousse-Joulin, M.A. d’Agostino, T. Marhadour, et al. . . . . 938
Relationship Between Arterial Stiffness and Stanford HAQ
Disability in RA Patients without Overt Arterial Disease
M.A. Crilly, H.J. Clark, V. Kumar, N.W. Scott,
A.G. MacDonald, D.J. Williams .................................... 946
Risk Factor Profiles for Atherosclerotic Cardiovascular
Disease in Black and Other Africans with Established RA
A. Solomon, B.F. Christian, G.R. Norton, A.J. Woodwiss,
P.H. Dessein .......................................................... 953
Health Literacy Predicts the Discrepancy Between Patient
and Provider Global Assessments of RA Activity at a
Public Urban Rheumatology Clinic J.M. Hirsh, D.J. Boyle,
Cytokine Profiles of Macrophage Activation Syndrome
Associated with Rheumatic Diseases
J. Maruyama, S. Inokuma ............................................. 967
White-matter Volume Reduction and the Protective Effect
of Immunosuppressive Therapy in SLE Patients with
Normal Appearance by Conventional MRI
J. Xu, Y. Cheng, P. Chai, et al ...................................... 974
Phenotype-Haplotype Correlation of IRF5 in SSC:
Role of 2 Haplotypes in Disease Severity
P. Dierdè, K. Dawidowicz, M. Guedj, et al ............................ 978
Early Detection of Cardiac Involvement in SSC Assessed
by Tissue-Doppler Echocardiography: Relationship
with Neurohormonal Activation and Endothelial
Dysfunction T. Dimitroulas, G. Giannakoulas,
K. Papadopoulou, et al ............................................. 993
ILD Associated with Anti-PM/ScI or Anti-Aminoacyl-tRNA
Synthetase Autoantibodies: A Similar Condition?
J-C. Lega, V. Cottin, N. Fabien, F. Thivolet-Bejui,
J-F. Cordier .......................................................... 1000
Estimating Indirect Costs in Primary Sjögren’s Syndrome
S.J. Bowman, Y. St. Pierre, N. Sutcliffe, et al ........................ 1010
Influence of STAT4 Polymorphism in Primary Sjögren’s
Syndrome R.J. Palomin-Morales, L-M. Díaz-Gallo,
T. Witte, J-M. Anaya, J. Martin .................................. 1016
Lack of Association Between the rs6920220 (G/A)
Polymorphism of the 6q23 Region and Biopsy-proven
Giant Cell Arteritis R. Palomin-Morales, O. Torres,
Minimally Important Difference for Patient-reported
Outcomes in Psoriatic Arthritis: Health Assessment
Questionnaire and Pain, Fatigue, and Global Visual
Analog Scales T. Kwok, J.E. Pope ................................. 1024
Serum Calprotectin as a Marker for Disease Activity and
Severity in Adult-onset Still’s Disease
S-Y. Jung, Y-B. Park, Y-J. Ha, K-H. Lee, S-K. Lee .................................................. 1029
Patient-derived Joint Counts Are a Potential Alternative
for Determining Disease Activity Score A. Kavanaugh,
S-J. Lee, H-H. Weng, Y. Chon, X-Y. Huang, S-L. Lin . . . . 1035
Single-joint Outcome Measures: Preliminary Validation of Patient-reported Outcomes and Physical Examination
A.E. Heald, E.J. Fudman, P. Anklesaria, P.J. Mease, on behalf of the 13G01 Study Team. 1042

Pediatric Rheumatology
Outcomes of Children Treated for Lyme Arthritis: Results of a Large Pediatric Cohort
H.O. Tory, D. Zurakowski, R.P. Sundel 1049

Images in Rheumatology
Cardiovascular MRI of Myocardial Fibrosis in DM
C. Arnold, H. Abdel-Aty, C. Tillmanns 1056
Intratendinous Power Doppler Changes Related to Patient Position in Seronegative Spondyloarthritis
M. Gutierrez, E. Filippucci, W. Grassi, M. Rosemffet 1057
Bilateral Subcutaneous Patellar Calcifications and Unilateral Bursitis in Scleroderma
S. Mathieu, M. Soubrier, J-J. Dubost 1060

Correspondence
Irish Smokers with RA Suffer More Than Their Nonsmoking Counterparts
L.C. Harty, D.J. Veale 1062
Reply D.L. Mattey, A. Brownfield, P.T. Dawes 1063
Race and MTX Pharmacogenetics in RA
P. Ranganathan, H. McLeod 1064
Reply M. Fisher, B. Cronstein 1064
Changes in Overall Health May Have Caused Recent Declines in ESR in Patients with RA
S.T. Anderson 1064
Reply T. Pincus, B. Abelson, T. Sokka 1065
Tocilizumab for RA with Chronic Hepatitis B Virus Infection without Antiviral Therapy
T. Nagashima, S. Minota 1066
Reply D. Wendling 1066
Is Weight Loss an Effective Strategy to Decrease Serum Uric Acid Levels Without Use of Antihyperuricemic Medications?
D.J. Harris 1067

Association of RNA Polymerase III Antibodies with Scleroderma Renal Crisis
B. Nguyen, S. Assassi, F.C. Arnett, M.D. Mayes 1068
Reply V. Codullo, C. Montecucco 1069

Letters
Effects of Early Rituximab Retreatment in RA Patients with an Inadequate Response After the First Cycle: Retrospective Arthritis Cohort Study
Curious Crystals: Chylous Arthritis in RA
S. Rohekar 1072
Anti-TNF Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis
H. Akbulut, S.S. Koca, M. Ozgen, A. Isik 1073
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
K. Hagihara, I. Kawase, T. Tanaka, T. Kishimoto 1075
Acute Pseudogout Following Intravenous Neridronate for Osteoporosis
S. Carda, M. Invernizzi, P.P. Sainaghi, C. Cisari 1076
Bosentan-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Y. Allanore, L. Moachon, E. Maury, A. Isvy, A. Kahan 1077
Scurvy as the Presenting Illness of Whipple’s Disease Exacerbated by Treatment with Etanercept in a Patient with Ankylosing Spondylitis
I. Hmamouchi, V. Costes, B. Combe, J. Morel 1078
Successful Use of Adalimumab for Treating RA with Autoimmune Sensorineural Hearing Loss: Two Birds with One Stone
J.M. Vergles, M. Radic, J. Kovacic, L. Salamon 1080

Correction
Less Radiographic Progression with Adalimumab plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Meetings in Rheumatology